LCM
MCID: MNT001
MIFTS: 72

Mantle Cell Lymphoma (LCM) malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Mantle Cell Lymphoma

Aliases & Descriptions for Mantle Cell Lymphoma:

Name: Mantle Cell Lymphoma 38 12 50 56 14
Lymphoma, Mantle Cell 50 29 13
Malignant Lymphoma, Lymphocytic, Intermediate Differentiation, Diffuse 69
Malignant Lymphoma - Lymphocytic, Intermediate Differentiation 69
Lymphoma, Mantle-Cell 42
Mantle Zone Lymphoma 56
Lymphoma Mantle-Cell 52
Lcm 56
Mcl 56

Characteristics:

Orphanet epidemiological data:

56
mantle cell lymphoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/1000000 (United States),1-9/100000 (Europe),1-9/100000 (France); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0050746
MeSH 42 D020522
Orphanet 56 ORPHA52416
MESH via Orphanet 43 D020522
ICD10 via Orphanet 34 C83.1
ICD10 33 C83.1

Summaries for Mantle Cell Lymphoma

NIH Rare Diseases : 50 mantle cell lymphoma (mcl) belongs to a group of diseases known as non-hodgkin’s lymphomas (nhl). nhl's are cancers that affect the the lymphatic system (part of the immune system). in mcl, there are cancerous b-cells (a type of immune system cell). the cancerous b-cells are within a region of the lymph node known as the mantle zone. although mcls are slow-growing cancers, the cancer is usually widespread by the time it is diagnosed. in these situations, treatment must be intensive since mcl can become life threatening within a short period of time. mcl accounts for 6% of all nhl's and is mostly found in males during their early 60s. last updated: 4/27/2016

MalaCards based summary : Mantle Cell Lymphoma, also known as lymphoma, mantle cell, is related to lymphoma and leukemia, and has symptoms including fatigue, fever and splenomegaly. An important gene associated with Mantle Cell Lymphoma is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and Akt Signaling. The drugs Imbruvica and Revlimid have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are Increased cell death HMECs cells and Increased viability with MLN4924 (a NAE inhibitor)

Disease Ontology : 12 A B-cell lymphocytic neoplasm due to CD5 positive antigen-naive pregerminal center B-cell within the mantle zone that surrounds normal germinal center follicles.

Wikipedia : 71 Mantle cell lymphoma (MCL) is a type of non-Hodgkin\'s lymphoma (NHL), comprising about 6% of NHL cases.... more...

Related Diseases for Mantle Cell Lymphoma

Diseases related to Mantle Cell Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 175)
id Related Disease Score Top Affiliating Genes
1 lymphoma 11.2
2 leukemia 10.4
3 male infertility 10.4 BCL2 CCND1
4 villoglandular endometrial endometrioid adenocarcinoma 10.4 ATM CCND1 TP53
5 parotitis 10.4 CCND1 CD5 SOX11
6 uterine ligament endometrioid adenocarcinoma 10.4 CCND1 CD5 SOX11
7 cervical verrucous carcinoma 10.4 CCND1 MDM2 TP53
8 b-cell lymphomas 10.4
9 hemorrhagic proctocolitis 10.4 CCND1 MTOR MYC
10 intraorbital meningioma 10.4 ATM MDM2 TP53
11 his bundle tachycardia 10.4 BCL2 CCND1 TP53
12 spastic paraplegia 1 10.4 BCL2 MDM2 TP53
13 chronic lymphocytic leukemia 10.4
14 rommen mueller sybert syndrome 10.3 MDM2 TP53
15 statin toxicity 10.3 BCL2 CCND1 TP53
16 trigeminal nerve neoplasm 10.3 CD5 MME
17 seminal vesicle chronic gonorrhea 10.3 ATM CCND1 CD5 MYC
18 cecum adenoma 10.3 BCL2 CCND1 MDM2 TP53
19 duodenal ulcer 10.3 ATM CD5 MYC TP53
20 nasopharyngeal carcinoma 10.3 ATM BCL2 MDM2 TP53
21 cleft palate cardiac defect ectrodactyly 10.3 BCL2 CCND1 TP53
22 vaginal adenosarcoma 10.3 BCL2 MME TP53
23 nevoid hypermelanosis, linear and whorled 10.3 BCL2 CCND1 MYC TP53
24 progressive external ophthalmoplegia with mitochondrial dna deletions, autosomal dominant 3 10.3 MCL1 MDM2 MYC TP53
25 placenta praevia 10.3 CCND1 MDM2 MYC TP53
26 pyloric antrum cancer 10.3 BCL2 BCL6 TP53
27 progesterone-receptor negative breast cancer 10.3 CCND1 MTOR TP53
28 spinal cord intramedullary teratoma 10.3 BCL6 CD5 TP53
29 ichthyosis, congenital, autosomal recessive 10 10.3 BCL2 BCL6 IGH
30 rubella panencephalitis 10.3 BCL2 BCL6
31 maxillary sinus cholesteatoma 10.3 BMI1 CCND1 TP53
32 thoracic outlet syndrome 10.3 BCL2 CCND1 MDM2 MYC TP53
33 barnicoat baraitser syndrome 10.3 CD19 CD5 MYC TP53
34 glucose-6-phosphate translocase deficiency 10.3 MDM2 MTOR MYC TP53
35 theileriasis 10.3 CCND1 CD5 MYC
36 post-surgical hypoinsulinemia 10.3 CCND1 CCND3 MDM2 MYC TP53
37 adult astrocytic tumour 10.3 MDM2 MTOR MYC TP53
38 glucosephosphate isomerase deficiency 10.3 BCL2 MDM2 MTOR TP53
39 small cell cancer of the lung, somatic 10.3 CCND1 CCND2 CCND3 MDM2 TP53
40 degenerative myopia 10.3 CD19 CD5 MME
41 malignant pleural solitary fibrous tumor 10.3 CCND1 MME MYC TP53
42 hodgkin lymphoma 10.2
43 penile disease 10.2 BCL6 CD19 CD5
44 lip cancer 10.2 BCL2 BCL6 CCND3
45 arteriosclerosis 10.2 BTK CD19 CD5
46 teebi naguib al awadi syndrome 10.2 BCL6 IGH MME
47 extraocular retinoblastoma 10.2 CCND1 CCND2 CCND3 MDM2 MYC TP53
48 integumentary system benign neoplasm 10.2 CCND1 CCND2 CCND3 MDM2 MYC TP53
49 basal ganglia disease 10.2 BCL6 CD19 CD5
50 childhood brain stem glioma 10.2 ATM CCND1 CD5 MME SOX11 TP53

Graphical network of the top 20 diseases related to Mantle Cell Lymphoma:



Diseases related to Mantle Cell Lymphoma

Symptoms & Phenotypes for Mantle Cell Lymphoma

Human phenotypes related to Mantle Cell Lymphoma:

56 32 (show all 9)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fatigue 56 32 Frequent (79-30%) HP:0012378
2 fever 56 32 Frequent (79-30%) HP:0001945
3 splenomegaly 56 32 Frequent (79-30%) HP:0001744
4 weight loss 56 32 Frequent (79-30%) HP:0001824
5 anorexia 56 32 Frequent (79-30%) HP:0002039
6 abnormality of the gastrointestinal tract 56 32 Occasional (29-5%) HP:0011024
7 lymphadenopathy 56 32 Very frequent (99-80%) HP:0002716
8 abnormality of bone marrow cell morphology 56 32 Frequent (79-30%) HP:0005561
9 b-cell lymphoma 56 32 Very frequent (99-80%) HP:0012191

GenomeRNAi Phenotypes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.63 BCL6 BMI1 CCND2 MDM2 MYC TP53
2 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.43 ATM BCL2 MCL1 MDM2 PMAIP1 TP53
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.36 ATM BCL2 MCL1 TP53
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.36 ATM BCL2 BTK CCND1 MCL1 MYC

MGI Mouse Phenotypes related to Mantle Cell Lymphoma:

44 (show all 17)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 ATM BCL2 BCL6 BTK CCND1 CCND2
2 cardiovascular system MP:0005385 10.37 MYC SOX11 TP53 ATM BCL2 BCL6
3 cellular MP:0005384 10.36 MCL1 MDM2 MTOR MYC SOX11 TP53
4 immune system MP:0005387 10.36 CCND3 CD19 CD5 EZH2 MCL1 MDM2
5 homeostasis/metabolism MP:0005376 10.33 ATM BCL2 BCL6 BTK CCND1 CCND2
6 endocrine/exocrine gland MP:0005379 10.32 MYC SOX11 TP53 ATM BCL2 BCL6
7 behavior/neurological MP:0005386 10.31 MYC TP53 ATM BCL2 CCND1 CCND2
8 growth/size/body region MP:0005378 10.31 ATM BCL2 BCL6 BTK CCND1 CCND3
9 integument MP:0010771 10.22 BCL2 BTK CCND1 CD19 CD5 EZH2
10 mortality/aging MP:0010768 10.2 ATM BCL2 BCL6 BTK CCND1 CCND2
11 digestive/alimentary MP:0005381 10.14 BCL2 BTK CCND1 CD19 MDM2 MYC
12 embryo MP:0005380 10.13 ATM EZH2 MCL1 MDM2 MTOR MYC
13 liver/biliary system MP:0005370 9.97 MYC TP53 BCL6 CCND2 CCND3 CD19
14 neoplasm MP:0002006 9.96 CCND1 CCND3 CD19 EZH2 MDM2 MYC
15 nervous system MP:0003631 9.93 MYC SOX11 TP53 ATM BCL2 CCND1
16 normal MP:0002873 9.73 BCL6 CCND1 CCND3 CD19 CD5 EZH2
17 reproductive system MP:0005389 9.28 ATM BCL2 BCL6 CCND1 CCND2 MCL1

Drugs & Therapeutics for Mantle Cell Lymphoma

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Imbruvica 17 46 IBRUTINIB Pharmacyclics Approved November of 2013/Approved February 2014
2
Revlimid 17 46 LENALIDOMIDE Celgene Approved June 2013
3
Velcade 17 46 BORTEZOMIB Millennium Pharmaceuticals Approved May 2003

Drugs for Mantle Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 495)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-02-2 5743
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
4
Etoposide Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33419-42-0 36462
5
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
6
Cytarabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 147-94-4 6253
7
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
8
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 174722-31-7 10201696
9
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 22916-47-8 4189
10
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1 159351-69-6 6442177
11
Thiotepa Approved Phase 4,Phase 2,Phase 3,Phase 1 52-24-4 5453
12
Lenograstim Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 135968-09-1
13
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
14
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 53-03-2 5865
15
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1 31703
16 Dexamethasone acetate Phase 4,Phase 3,Phase 1,Phase 2 1177-87-3
17 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19
protease inhibitors Phase 4,Phase 3,Phase 1,Phase 2
20 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
21 HIV Protease Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
22 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Dexamethasone 21-phosphate Phase 4,Phase 3,Phase 1,Phase 2
25 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
27 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
30 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
31 Etoposide phosphate Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
33 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Antiemetics Phase 4,Phase 3,Phase 1,Phase 2
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Antifungal Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Antilymphocyte Serum Phase 4,Phase 2,Phase 3,Phase 1
38 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
41 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
43 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 BB 1101 Phase 4,Phase 3,Phase 1,Phase 2
45 Autonomic Agents Phase 4,Phase 3,Phase 1,Phase 2
46 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
47 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
49
Cyclosporine Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
50
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1 104987-11-3 445643 439492

Interventional clinical trials:

(show top 50) (show all 942)
id Name Status NCT ID Phase
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4
2 EDOCH Alternating With DHAP for New Diagnosed Younger MCL Recruiting NCT02858804 Phase 4
3 An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting NCT01833039 Phase 4
4 Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma Active, not recruiting NCT01180049 Phase 4
5 Chemotherapy Followed by Radiation Therapy and Peripheral Stem Cell Transplant Compared With Chemotherapy Plus Interferon Alfa in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma Unknown status NCT00016887 Phase 3
6 Fludarabine and Cyclophosphamide With or Without Rituximab in Treating Patients With Previously Untreated Mantle Cell Lymphoma Unknown status NCT00641095 Phase 3
7 Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL Unknown status NCT00209222 Phase 3
8 Radiolabeled Monoclonal Antibody in the Detection and Staging of Patients With Non-Hodgkin's Lymphoma Unknown status NCT00003337 Phase 3
9 Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma Unknown status NCT00003338 Phase 2, Phase 3
10 Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00052936 Phase 3
11 Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma Unknown status NCT00053768 Phase 3
12 Combination Chemotherapy Plus Filgrastim With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma Unknown status NCT00028717 Phase 3
13 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3
14 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
15 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
16 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
17 Interferon Alfa-2b Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Hodgkin's Disease or Non-Hodgkin's Lymphoma Unknown status NCT00003924 Phase 3
18 Combination Chemotherapy Given With Radiation Therapy or Radiation Therapy Alone in Treating Patients With Early-Stage Hodgkin's Disease Unknown status NCT00002987 Phase 3
19 Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy Completed NCT01646021 Phase 3
20 Monoclonal Antibody Therapy in Treating Patients With Follicular or Mantle Cell Lymphoma Completed NCT00003280 Phase 3
21 Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL) Completed NCT00117598 Phase 3
22 Study to Assess the Effect of Treatment With Bendamustine in Combination With Rituximab on QT Interval in Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) Completed NCT01073163 Phase 3
23 Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab Completed NCT01456351 Phase 3
24 Mantel Cell Lymphoma Efficacy of Rituximab Maintenance Completed NCT00921414 Phase 3
25 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab Completed NCT00991211 Phase 3
26 A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma Completed NCT00269113 Phase 3
27 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
28 Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00075478 Phase 3
29 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
30 Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy Completed NCT00003341 Phase 3
31 Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed NCT00278421 Phase 3
32 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed NCT00278408 Phase 3
33 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
34 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
35 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
36 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
37 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3
38 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
39 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
40 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
41 Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma Completed NCT00004112 Phase 3
42 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
43 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
44 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
45 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
46 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
47 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
48 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
49 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
50 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3

Search NIH Clinical Center for Mantle Cell Lymphoma

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Mantle Cell Lymphoma cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: lymphoma, mantle-cell

Genetic Tests for Mantle Cell Lymphoma

Genetic tests related to Mantle Cell Lymphoma:

id Genetic test Affiliating Genes
1 Mantle Cell Lymphoma 29

Anatomical Context for Mantle Cell Lymphoma

MalaCards organs/tissues related to Mantle Cell Lymphoma:

39
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Monocytes, Colon

Publications for Mantle Cell Lymphoma

Articles related to Mantle Cell Lymphoma:

(show top 50) (show all 1019)
id Title Authors Year
1
Recommendations for Clinical Trial Development in Mantle Cell Lymphoma. ( 28040733 )
2017
2
Gastrointestinal mantle cell lymphoma with isolated mass and multiple lymphomatous polyposis: report of two cases. ( 28451951 )
2017
3
SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. ( 28533307 )
2017
4
Novel agents in mantle cell lymphoma. ( 28480764 )
2017
5
Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. ( 28416797 )
2017
6
Cyclin D1-negative blastoid mantle cell lymphoma exhibiting cleaved to bilobated cytomorphology. ( 28495928 )
2017
7
Mantle cell lymphoma with central nervous system involvement simulating bilateral subdural hematomas. ( 28063897 )
2017
8
Second-line rituximab, lenalidomide, and bendamustine (R2B) in mantle cell lymphoma: a phase 2 clinical trial of the Fondazione Italiana Linfomi. ( 28082342 )
2017
9
Mantle Cell Lymphoma: Contemporary Diagnostic and Treatment Perspectives in the Age of Personalized Medicine. ( 28404221 )
2017
10
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity. ( 28457728 )
2017
11
SOX-11 detection in decalcified bone marrow tissue in mantle cell lymphoma patients, methodological issue on reproducibility and validity-reply. ( 28461033 )
2017
12
Mantle Cell Lymphoma Presenting as a Subcutaneous Soft Tissue Mass With an Unusual Appearance. ( 28081018 )
2017
13
Hyperfractionated Cyclophosphamide, Vincristine, Doxorubicin, and Dexamethasone Chemotherapy in Mantle Cell Lymphoma Patients Is Associated with Higher Rates of Hematopoietic Progenitor Cell Mobilization Failure despite Plerixafor Rescue. ( 28434928 )
2017
14
Correction: ROS-Induced CXCR4 Signaling Regulates Mantle Cell Lymphoma (MCL) Cell Survival and Drug Resistance in the Bone Marrow Microenvironment via Autophagy. ( 28373366 )
2017
15
The drive to generate multiple forms of oncogenic cyclin D1 transcripts in mantle cell lymphoma. ( 28503306 )
2017
16
Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma. ( 28055107 )
2017
17
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. ( 28388555 )
2017
18
Triple-hit blastoid mantle cell lymphoma presenting like acute leukemia. ( 28473415 )
2017
19
Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. ( 28457696 )
2017
20
SOX11 regulates the pro-apoptosis signal pathway and predicts a favorable prognosis of mantle cell lymphoma. ( 28429312 )
2017
21
First reported case of disseminated Nocardia kroppenstedtii sp nov. infection presenting with brain abscess and endocarditis in an immunocompromised patient with mantle cell lymphoma: challenges in diagnosis and treatment. ( 28062425 )
2017
22
Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6/STAT3/PI3K Axis. ( 28529032 )
2017
23
Phase II Study of Bortezomib in Combination with Cyclophosphamide and Rituximab for Relapsed or Refractory Mantle Cell Lymphoma. ( 28408615 )
2017
24
Expression of LEF1 in mantle cell lymphoma. ( 28038713 )
2017
25
Persistence of a t(11;14)-positive clone in a patient with mantle cell lymphoma for 20A years. ( 28396772 )
2017
26
Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma-a "real world" study. ( 28066928 )
2017
27
Incidence and survival trends in mantle cell lymphoma. ( 28444739 )
2017
28
Role of SOX11 and Genetic Events Cooperating with Cyclin D1 in Mantle Cell Lymphoma. ( 28466437 )
2017
29
Androgen receptor expression in mantle cell lymphoma: Potential novel therapeutic implications. ( 28115200 )
2017
30
Complementarity determining region-independent recognition of a superantigen by B-cell antigen receptors of mantle cell lymphoma. ( 27582571 )
2016
31
Discrete vacuoles in lymphocytes as a subtle clue to mantle cell lymphoma. ( 28092871 )
2016
32
Validation of R-MIPI and prognostic value of immunoglobulin light chain restriction in mantle cell lymphoma. ( 27125335 )
2016
33
Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status. ( 27074052 )
2016
34
Diagnostic utility of SOX11 immunohistochemistry in differentiating cutaneous spread of mantle cell lymphoma from primary cutaneous B-cell lymphomas. ( 26762898 )
2016
35
From Minimal Residual Disease to Maintenance Therapy: Optimizing Tools for Treatment of Mantle Cell Lymphoma. ( 27083467 )
2016
36
Bortezomib for the treatment of mantle cell lymphoma: an update. ( 27493710 )
2016
37
Pleomorphic mantle cell lymphoma morphologically mimicking diffuse large B-cell lymphoma: common cyclin D1 negativity and a simple immunohistochemical algorithm to avoid the diagnostic pitfall. ( 28032914 )
2016
38
Diagnostic and therapeutic update of mantle cell lymphoma (MCL): analysis of seven cases treated in a centre in one year. ( 27110283 )
2016
39
Ibrutinib-related atrial fibrillation in patients with mantle cell lymphoma. ( 27087288 )
2016
40
CCND1-IGH Fusion-Amplification and MYC Copy Number Gain in a Case of Pleomorphic Variant Mantle Cell Lymphoma. ( 28028120 )
2016
41
Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. ( 27153197 )
2016
42
Pure red cell aplasia revealing nonnodal mantle cell lymphoma. ( 27322005 )
2016
43
POINT: The Role of Stem Cell Transplantation in Mantle Cell Lymphoma. ( 27987196 )
2016
44
Wells' syndrome with a clinicopathological correlation associated with mantle-cell lymphoma. ( 26999270 )
2016
45
Endobronchial involvement of mantle cell lymphoma: A case report. ( 27536549 )
2016
46
Multiple cutaneous metastases as the first sign of mantle cell lymphoma associated with multiple HPVA 52-positive squamous cell carcinomas of the skin. ( 27550714 )
2016
47
Single-agent cytarabine is insufficient for the treatment of human mantle cell lymphoma in mouse xenograft model. ( 27468882 )
2016
48
ZGDHu-1 promotes apoptosis of mantle cell lymphoma cells. ( 28035065 )
2016
49
SOXC and MiR17-92 gene expression profiling defines two subgroups with different clinical outcome in mantle cell lymphoma. ( 26998831 )
2016
50
Toll-Like Receptor 1/2 and 5 Ligands Enhance the Expression of Cyclin D1 and D3 and Induce Proliferation in Mantle Cell Lymphoma. ( 27123851 )
2016

Variations for Mantle Cell Lymphoma

ClinVar genetic disease variations for Mantle Cell Lymphoma:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7268A> G (p.Glu2423Gly) single nucleotide variant Pathogenic rs121434221 GRCh37 Chromosome 11, 108199926: 108199926
2 ATM NM_000051.3(ATM): c.7251_7253dupGAA (p.Lys2418_Arg2419insLys) duplication Pathogenic rs796051857 GRCh38 Chromosome 11, 108329182: 108329184
3 ATM NM_000051.3(ATM): c.4081C> T (p.Gln1361Ter) single nucleotide variant Pathogenic rs121434222 GRCh37 Chromosome 11, 108158414: 108158414

Cosmic variations for Mantle Cell Lymphoma:

9 (show top 50) (show all 285)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM3733325 ZNF296 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.488G>A p.G163D 6
2 COSM3733324 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.6190G>A p.E2064K 6
3 COSM3733267 UBR5 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.8147C>G p.S2716* 6
4 COSM44571 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.581T>G p.L194R 6
5 COSM44972 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.831T>A p.C277* 6
6 COSM10662 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.743G>A p.R248Q 6
7 COSM6901 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.559+1G>A p.? 6
8 COSM10667 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.646G>A p.V216M 6
9 COSM43826 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.706T>A p.Y236N 6
10 COSM11450 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.644G>T p.S215I 6
11 COSM44962 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.774A>T p.E258D 6
12 COSM10648 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.524G>A p.R175H 6
13 COSM10749 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.830G>T p.C277F 6
14 COSM44309 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.440T>G p.V147G 6
15 COSM10659 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.817C>T p.R273C 6
16 COSM10786 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.949C>T p.Q317* 6
17 COSM10758 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.659A>G p.Y220C 6
18 COSM10705 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.586C>T p.R196* 6
19 COSM10883 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.731G>A p.G244D 6
20 COSM44467 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.497C>G p.S166* 6
21 COSM11089 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.584T>C p.I195T 6
22 COSM43651 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.763A>T p.I255F 6
23 COSM10656 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.742C>T p.R248W 6
24 COSM43814 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.587G>C p.R196P 6
25 COSM10724 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.839G>C p.R280T 6
26 COSM43846 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.487T>C p.Y163H 6
27 COSM10660 TP53 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.818G>A p.R273H 6
28 COSM3733438 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2400G>T p.Q800H 6
29 COSM3733439 SMC1A haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2398C>G p.Q800E 6
30 COSM3733301 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2641G>A p.D881N 6
31 COSM3733500 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3565C>G p.R1189G 6
32 COSM3733331 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2897G>A p.R966Q 6
33 COSM3733382 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3109A>T p.N1037Y 6
34 COSM3733287 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4600C>A p.Q1534K 6
35 COSM3733266 SMARCA4 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3186C>G p.H1062Q 6
36 COSM3733321 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1126C>T p.R376W 6
37 COSM3733285 SI haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1825T>C p.W609R 6
38 COSM3733430 SALL3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.3044C>T p.S1015F 6
39 COSM3733372 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2083C>T p.R695* 6
40 COSM3733347 ROBO2 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.964G>A p.D322N 6
41 COSM3733492 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.1535T>A p.L512* 6
42 COSM3733293 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2570G>T p.R857L 6
43 COSM171725 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.838G>T p.E280* 6
44 COSM3733320 RB1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.52G>A p.A18T 6
45 COSM363436 POT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.803G>A p.G268D 6
46 COSM3733311 POT1 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.131G>A p.C44Y 6
47 COSM3733318 PLXNB3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4099C>T p.R1367C 6
48 COSM3733404 PLXNB3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.4141C>T p.L1381F 6
49 COSM3733278 PLXNB3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.141C>G p.F47L 6
50 COSM3733408 PLXNB3 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,mantle cell lymphoma c.2941C>T p.R981C 6

Copy number variations for Mantle Cell Lymphoma from CNVD:

7 (show all 39)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 44978 10 6600000 12200000 Loss Mantle cell lymphoma
2 49103 11 102900000 110400000 Loss ACAT Mantle cell lymphoma
3 49104 11 102900000 110400000 Loss ATM Mantle cell lymphoma
4 49105 11 102900000 110400000 Loss CUL5 Mantle cell lymphoma
5 49106 11 102900000 110400000 Loss FDX1 Mantle cell lymphoma
6 49107 11 102900000 110400000 Loss NPAT Mantle cell lymphoma
7 49108 11 102900000 110400000 Loss RAB39 Mantle cell lymphoma
8 49703 11 110400000 112500000 Loss Mantle cell lymphoma
9 49990 11 112500000 114500000 Loss TMPRSS5 Mantle cell lymphoma
10 49991 11 112500000 114500000 Loss USP28 Mantle cell lymphoma
11 49992 11 112500000 114500000 Loss ZW10 Mantle cell lymphoma
12 54401 11 43500000 48800000 Loss TP53I11 Mantle cell lymphoma
13 60881 11 92800000 97200000 Loss MAML2 Mantle cell lymphoma
14 61262 11 97200000 102100000 Loss BIRC2 Mantle cell lymphoma
15 61263 11 97200000 102100000 Loss BIRC3 Mantle cell lymphoma
16 74176 13 101700000 104800000 Loss BIVM Mantle cell lymphoma
17 74177 13 101700000 104800000 Loss ERCC5 Mantle cell lymphoma
18 74178 13 101700000 104800000 Loss KDELC1 Mantle cell lymphoma
19 74694 13 110300000 115169878 Loss C13orf11 Mantle cell lymphoma
20 74695 13 110300000 115169878 Loss C13orf17 Mantle cell lymphoma
21 74696 13 110300000 115169878 Loss CUL4A Mantle cell lymphoma
22 74697 13 110300000 115169878 Loss GRTP1 Mantle cell lymphoma
23 74698 3 117011831 117647068 Loss LAMP Mantle cell lymphoma
24 74699 13 110300000 115169878 Loss TFDP1 Mantle cell lymphoma
25 77990 13 48877883 49056026 Deletion RB1 Mantle cell lymphoma
26 79883 13 79000000 95000000 Copy number miR-17-92 Mantle cell lymphoma
27 80925 13 99300000 101700000 Loss PCCA Mantle cell lymphoma
28 118115 17 7571720 7590868 Mutation P53 Mantle cell lymphoma
29 141432 2 210288771 210598834 Deletion MAP2 Mantle cell lymphoma
30 143512 2 237300000 243199373 Loss Mantle cell lymphoma
31 170852 3 160700000 167600000 Loss SLITRK3 Mantle cell lymphoma
32 245172 9 102600000 108200000 Loss INVS Mantle cell lymphoma
33 248837 9 137400000 141213431 Loss TRAF2 Mantle cell lymphoma
34 250734 9 21967751 21994490 Deletion CDKN2A Mantle cell lymphoma
35 252714 9 36300000 38400000 Loss MELK Mantle cell lymphoma
36 254747 9 68700000 72200000 Loss TJP2 Mantle cell lymphoma
37 256309 9 91800000 93900000 Loss DIRAS2 Mantle cell lymphoma
38 256992 9 99300000 102600000 Loss GPR51 Mantle cell lymphoma
39 256993 9 99300000 102600000 Loss TBC1D2 Mantle cell lymphoma

Expression for Mantle Cell Lymphoma

Search GEO for disease gene expression data for Mantle Cell Lymphoma.

Pathways for Mantle Cell Lymphoma

Pathways related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show top 50) (show all 90)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 ATM BCL2 BTK CCND1 CCND2 CCND3
2
Show member pathways
13.49 BCL2 BTK CCND1 CCND2 CCND3 MDM2
3
Show member pathways
13.11 ATM BCL2 CCND1 CCND2 MDM2 MTOR
4
Show member pathways
13.05 ATM BCL6 MDM2 MTOR PMAIP1 TP53
5
Show member pathways
12.92 ATM BCL2 MCL1 MDM2 MYC PMAIP1
6
Show member pathways
12.8 BTK CD19 MDM2 MTOR TP53
7 12.77 BCL2 CCND1 MDM2 MTOR MYC TP53
8
Show member pathways
12.74 ATM CCND1 MDM2 MYC TP53
9
Show member pathways
12.67 BCL2 BCL6 CCND1 MTOR MYC
10
Show member pathways
12.67 ATM CCND1 CCND2 CCND3 MDM2 MYC
11
Show member pathways
12.63 CCND1 MDM2 MTOR MYC TP53
12
Show member pathways
12.63 CCND1 CCND2 CCND3 MYC TP53
13 12.61 ATM CCND1 CCND2 CCND3 MDM2 TP53
14 12.6 BCL2 CCND1 CCND2 CCND3 CD19 MCL1
15
Show member pathways
12.57 BCL2 CCND1 CCND2 MTOR MYC
16
Show member pathways
12.54 ATM BCL2 MDM2 MTOR TP53
17 12.53 ATM CCND1 CCND2 CCND3 MYC TP53
18 12.52 CCND1 CCND2 CCND3 MYC TP53
19
Show member pathways
12.46 ATM CCND1 CCND2 CCND3 TP53
20
Show member pathways
12.46 BCL2 CCND1 MDM2 MTOR MYC TP53
21 12.46 ATM CCND1 CCND2 CCND3 MDM2 MYC
22
Show member pathways
12.44 BCL6 BTK CD19 MYC
23
Show member pathways
12.42 CCND1 CCND2 CCND3 IGH MDM2 MTOR
24
Show member pathways
12.41 CCND1 MDM2 MTOR MYC TP53
25 12.4 BCL2 CD19 MDM2 MYC TP53
26 12.4 CCND1 MDM2 MTOR MYC TP53
27 12.4 CCND1 CCND2 CCND3 MDM2 PMAIP1 TP53
28
Show member pathways
12.39 BCL6 BTK CD19 MTOR
29
Show member pathways
12.37 ATM CCND1 CCND2 CCND3 MDM2 MYC
30
Show member pathways
12.36 ATM BCL2 CCND1 MDM2 TP53
31 12.32 ATM BCL6 BMI1 CCND2 MDM2 MYC
32 12.31 BCL2 MCL1 MYC PMAIP1
33
Show member pathways
12.29 CCND1 CCND2 CCND3 MYC
34
Show member pathways
12.29 BCL2 CCND1 CCND2 CCND3 MCL1 MTOR
35 12.26 CCND1 CCND2 MYC TP53
36
Show member pathways
12.24 CCND1 CCND2 CCND3 MDM2 MTOR MYC
37 12.22 CCND1 CCND2 CCND3 MYC
38 12.22 BCL2 CCND1 MDM2 MTOR TP53
39
Show member pathways
12.19 ATM BCL6 CCND1 CCND2 MDM2
40 12.19 ATM BCL2 CCND1 MDM2 MTOR MYC
41
Show member pathways
12.17 CCND1 MDM2 MYC TP53
42 12.17 BCL2 BCL6 MCL1 MDM2 PMAIP1 TP53
43 12.17 ATM BCL2 BMI1 CCND1 CCND2 EZH2
44
Show member pathways
12.15 BCL2 BTK CCND2 MYC
45 12.1 CCND1 MDM2 MTOR MYC TP53
46 12.08 CCND1 MDM2 MTOR MYC TP53
47 12.08 BCL2 BCL6 CCND1 MCL1 MYC TP53
48 12.05 BCL2 BMI1 MDM2 MTOR TP53
49
Show member pathways
12.04 ATM BCL6 PMAIP1 TP53
50 11.95 CCND1 CCND3 MDM2 MYC TP53

GO Terms for Mantle Cell Lymphoma

Cellular components related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.77 BCL2 CD19 MDM2 MYC TP53
2 mitochondrial outer membrane GO:0005741 9.62 BCL2 MCL1 MTOR PMAIP1
3 nucleoplasm GO:0005654 9.44 ATM BCL2 BCL6 BMI1 CCND1 CCND2
4 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.13 CCND1 CCND2 CCND3
5 cytoplasm GO:0005737 10.13 ATM BCL2 BMI1 BTK CCND1 CCND2
6 nucleus GO:0005634 10.06 ATM BCL2 BCL6 BMI1 BTK CCND1

Biological processes related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 45)
id Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.97 BCL6 BTK CCND3 EZH2
2 negative regulation of gene expression GO:0010629 9.95 EZH2 MDM2 MYC SOX11
3 positive regulation of protein phosphorylation GO:0001934 9.94 CCND1 CCND2 CCND3 MTOR
4 cell cycle arrest GO:0007050 9.93 ATM MTOR MYC TP53
5 negative regulation of apoptotic process GO:0043066 9.91 BCL2 BCL6 CCND2 MCL1 MDM2 MYC
6 regulation of gene expression GO:0010468 9.88 BCL2 BMI1 EZH2 MDM2 MYC
7 post-embryonic development GO:0009791 9.86 ATM BCL2 MTOR
8 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.84 ATM MDM2 TP53
9 ovarian follicle development GO:0001541 9.81 ATM BCL2 MYC
10 positive regulation of cell cycle GO:0045787 9.8 CCND1 MDM2 MYC
11 cellular response to DNA damage stimulus GO:0006974 9.8 ATM BCL2 BCL6 CCND1 MYC PMAIP1
12 cellular response to glucose starvation GO:0042149 9.79 BCL2 PMAIP1 TP53
13 response to steroid hormone GO:0048545 9.78 BCL2 CCND1 MDM2
14 cellular response to organic substance GO:0071310 9.77 BCL2 CCND1 MDM2
15 negative regulation of autophagy GO:0010507 9.77 BCL2 MCL1 MTOR
16 response to gamma radiation GO:0010332 9.76 BCL2 MYC TP53
17 liver regeneration GO:0097421 9.75 CCND1 EZH2 MYC
18 positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway GO:1900740 9.72 BCL2 PMAIP1 TP53
19 regulation of cell cycle GO:0051726 9.72 ATM BCL2 CCND1 CCND2 CCND3
20 positive regulation of intrinsic apoptotic signaling pathway GO:2001244 9.71 BCL2 PMAIP1 TP53
21 response to magnesium ion GO:0032026 9.7 CCND1 MDM2
22 cell aging GO:0007569 9.7 BCL2 MTOR TP53
23 determination of adult lifespan GO:0008340 9.69 ATM TP53
24 growth GO:0040007 9.69 BCL2 MTOR
25 oocyte development GO:0048599 9.69 ATM BCL2
26 cellular response to gamma radiation GO:0071480 9.69 ATM MDM2 TP53
27 positive regulation of DNA damage response, signal transduction by p53 class mediator GO:0043517 9.68 ATM PMAIP1
28 positive regulation of glial cell proliferation GO:0060252 9.68 MTOR MYC
29 positive regulation of histone deacetylation GO:0031065 9.68 BCL6 TP53
30 cellular response to X-ray GO:0071481 9.67 ATM CCND2
31 mitotic G1 DNA damage checkpoint GO:0031571 9.67 CCND1 TP53
32 positive regulation of cyclin-dependent protein serine/threonine kinase activity GO:0045737 9.67 CCND1 CCND2 CCND3
33 response to iron ion GO:0010039 9.63 BCL2 CCND1 MDM2
34 regulation of apoptotic process GO:0042981 9.63 ATM BCL2 BCL6 MCL1 PMAIP1 TP53
35 positive regulation of neuron maturation GO:0014042 9.62 BCL2 MTOR
36 re-entry into mitotic cell cycle GO:0000320 9.62 CCND1 MYC
37 replicative senescence GO:0090399 9.61 ATM MME TP53
38 negative regulation of transcription from RNA polymerase II promoter GO:0000122 9.61 BCL6 BMI1 CCND1 CCND3 EZH2 MDM2
39 regulation of mitochondrial membrane permeability GO:0046902 9.58 BCL2 PMAIP1 TP53
40 cellular response to actinomycin D GO:0072717 9.57 MDM2 TP53
41 cellular response to hypoxia GO:0071456 9.1 BCL2 MDM2 MTOR MYC PMAIP1 TP53
42 apoptotic process GO:0006915 10.14 ATM BCL2 BTK MCL1 PMAIP1 TP53
43 cell proliferation GO:0008283 10.05 BCL2 CD5 MYC SOX11 TP53
44 positive regulation of gene expression GO:0010628 10.04 MDM2 MTOR MYC SOX11 TP53
45 positive regulation of cell proliferation GO:0008284 10.03 BCL2 CCND1 CCND2 MDM2 MYC SOX11

Molecular functions related to Mantle Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.58 ATM BCL2 BCL6 BMI1 BTK CCND1
2 protein kinase binding GO:0019901 9.55 CCND1 CCND2 CCND3 MTOR TP53
3 BH3 domain binding GO:0051434 8.96 BCL2 MCL1

Sources for Mantle Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....